- Home
- APLT vs XLO Comparison
APLT vs XLO Comparison
Compare APLT & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLT | XLO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 41.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | APLT | XLO |
|---|---|---|
| Price | $0.12 | $0.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.25 | ★ $2.00 |
| AVG Volume (30 Days) | ★ 27.2M | 528.0K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,000,000.00 | ★ $31,804,000.00 |
| Revenue This Year | $124.18 | $589.60 |
| Revenue Next Year | $66.67 | $38.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $0.11 | $0.62 |
| 52 Week High | $1.50 | $1.70 |
Technical Indicators
Market Signals| Indicator | APLT | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 25.40 | 35.82 |
| Support Level | $0.21 | $0.68 |
| Resistance Level | $0.26 | $0.73 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 5.13 | 2.13 |
Price Performance
Historical ComparisonAbout APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.